Market Overview

Akcea Therapeutics, PTC Therapeutics Partner to Commercialize Two Rare Disease Drugs in Latin America; PTC To Gain Exclusive Rights To TEGSEDI and WAYLIVRA In These Areas And Akcea To Receive Licensing Fee Of $18M

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: News Contracts Press Releases

 

Related Articles (IONS + AKCA)

A Preview Of Allscripts Healthcare's Q2 Earnings

GoDaddy's Q2 Earnings Preview